VOR supply chain intelligence for Vor Biopharma Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Vor Biopharma Inc. (VOR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| REMEGEN | REMEGEN | 92% | In June 2025, we entered into a license agreement with RemeGen (the “Telitacicept License Agreement”) granting us an exclusive (even as to RemeGen) license under RemeGen’s patents and know-how to exp… |
| TELITACICEPT-LICENSE-AGREEMENT | TELITACICEPT-LICENSE-AGREEMENT | 90% | The Company incurred $ 0.2 million in transaction costs related to the Telitacicept License Agreement during the year ended December 31, 2025. |
| THE-TRUSTEES-OF-COLUMBIA-UNIVERSITY-IN-THE-CITY- | THE-TRUSTEES-OF-COLUMBIA-UNIVERSITY-IN-THE-CITY- | 90% | including the exclusive license agreement with The Trustees of Columbia University in the City of New York |
| U-S-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | U-S-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | 90% | patent license agreement with the U.S. Department of Health and Human Services, as represented by National Cancer Institute of the National Institutes of Health |
| A | Agilent Technologies, Inc. | 72% | Reciprocal relationship from A graph: Reciprocal relationship from VOR graph: Reciprocal relationship from A graph: Reciprocal relationship from VOR graph: lth authorities. Agreements with such manuf… |
| A | Agilent Technologies, Inc. | 72% | lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any performance failure on the part of our … |
| JAZZ | Jazz Pharmaceuticals plc | 72% | Reciprocal relationship from JAZZ graph: Reciprocal relationship from VOR graph: Reciprocal relationship from JAZZ graph: Reciprocal relationship from VOR graph: Reciprocal relationship from JAZZ gra… |
| JAZZ | Jazz Pharmaceuticals plc | 72% | Vanflyta (quizartinib), Jazz Pharmaceuticals plc’s Vyxeos (daunorubicin and cytarabine), Novartis International AG’s Rydapt (midostaurin), Pfizer Inc.’s Mylotarg (gemtuzumab ozogamicin) and Daurismo … |
| JBIO | Jade Biosciences, Inc. | 72% | Reciprocal relationship from JBIO graph: Reciprocal relationship from VOR graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from VOR graph: Reciprocal relationship from JBIO gra… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from VOR graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from VOR graph: Reciprocal relationship from JNJ graph:… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from VOR graph: lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need … |
| MYGN | Myriad Genetics, Inc. | 72% | lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any performance failure on the part of our … |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from VOR graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from VOR graph: Reciprocal relationship from NVSEF … |
| NVSEF | Novartis AG | 72% | lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any performance failure on the part of our … |
| PRTC | PureTech Health plc | 72% | Reciprocal relationship from PRTC graph: Reciprocal relationship from VOR graph: Reciprocal relationship from PRTC graph: er the Group participates in the policy making processes of the investee, whe… |
| RIGL | Rigel Pharmaceuticals, Inc. | 72% | arabine), Novartis International AG’s Rydapt (midostaurin), Pfizer Inc.’s Mylotarg (gemtuzumab ozogamicin) and Daurismo (glasdegib), Rigel Pharmaceuticals, Inc.’s Rezlidhia (olutasidenib), and Syndax… |
| RIGL | Rigel Pharmaceuticals, Inc. | 72% | Reciprocal relationship from RIGL graph: Reciprocal relationship from VOR graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from VOR graph: arabine), Novartis International AG’s… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any performance failure on the part of our … |
| SGMO | Sangamo Therapeutics, Inc. | 72% | Reciprocal relationship from SGMO graph: Reciprocal relationship from VOR graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from VOR graph: Reciprocal relationship from SGMO gra… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from VOR graph: lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need… |
| SNYNF | Sanofi | 72% | lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any performance failure on the part of our … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| TCGX | TCGX | 90% | The Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 5,338,078 shares (the 'Shares') of the Company's common stock, at a price per Share of $14.05, for gross… |
| TCGX | TCGX | 90% | Reciprocal relationship from TCGX graph: Reciprocal relationship from VOR graph: Reciprocal relationship from TCGX graph: Reciprocal relationship from VOR graph: The Company, in a private placement, … |
| A | Agilent Technologies, Inc. | 72% | Reciprocal relationship from A graph: Reciprocal relationship from VOR graph: lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to … |
| A | Agilent Technologies, Inc. | 72% | lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any performance failure on the part of our … |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from VOR graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from VOR graph: focused sales, marketing and commerci… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | focused sales, marketing and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved. Th… |
| GRFS | Grifols, S.A. | 72% | focused sales, marketing and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved. Th… |
| GRFS | Grifols, S.A. | 72% | Reciprocal relationship from GRFS graph: Reciprocal relationship from VOR graph: focused sales, marketing and commercial support infrastructure to sell, or participate in sales activities with our co… |
| JBIO | Jade Biosciences, Inc. | 72% | Reciprocal relationship from JBIO graph: Reciprocal relationship from VOR graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from VOR graph: Reciprocal relationship from JBIO gra… |
| JNJ | Johnson & Johnson | 72% | e have not yet established a commercial organization or distribution capabilities. We plan to build focused capabilities in various regions worldwide (the United States, South America, Europe, Japan,… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from VOR graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from VOR graph: Reciprocal relationship from JNJ graph:… |
| MYGN | Myriad Genetics, Inc. | 72% | nancial condition, results of operations and prospects. Our product candidates may compete with other product candidates and products for access to manufacturing facilities and other supplies. There … |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from VOR graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from VOR graph: Reciprocal relationship from MYGN gra… |
| NVSEF | Novartis AG | 72% | focused sales, marketing and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved. Th… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from VOR graph: focused sales, marketing and commercial support infrastructure to sell, or participate in sales activities with our c… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | egulatory and commercialization activities and costs in the licensed territory, including the conduct of clinical trials and regulatory submissions. The Telitacicept License Agreement established a j… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from VOR graph: egulatory and commercialization activities and costs in the licensed territory, including the conduct of clinical tria… |
| RNAC | Cartesian Therapeutics, Inc. | 72% | focused sales, marketing and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved. Th… |
| RNAC | Cartesian Therapeutics, Inc. | 72% | Reciprocal relationship from RNAC graph: Reciprocal relationship from VOR graph: Reciprocal relationship from RNAC graph: Reciprocal relationship from VOR graph: Reciprocal relationship from RNAC gra… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | Reciprocal relationship from SGMO graph: Reciprocal relationship from VOR graph: lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need … |
| SGMO | Sangamo Therapeutics, Inc. | 72% | lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any performance failure on the part of our … |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from VOR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from VOR graph: Reciprocal relationship from SNYNF … |
| SNYNF | Sanofi | 72% | nancial condition, results of operations and prospects. Our product candidates may compete with other product candidates and products for access to manufacturing facilities and other supplies. There … |
| REMEGEN-CO-LTD | REMEGEN-CO-LTD | 62% | . Depreciation expense for the three months ended March 31, 2025 was $ 0.8 million. 6. Accrued Liabilities Accrued liabilities consisted of the following: March 31, December 31, (in thousands) 2026 2… |
| TCG-CROSSOVER-MANAGEMENT-LLC | TCG-CROSSOVER-MANAGEMENT-LLC | 62% | . Depreciation expense for the three months ended March 31, 2025 was $ 0.8 million. 6. Accrued Liabilities Accrued liabilities consisted of the following: March 31, December 31, (in thousands) 2026 2… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| VOR-DEBT-13409 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2021-12-31. |
| VOR-DEBT | Debt stack $2.9M | 90% | Market cache reports total debt of $2.9M. |
| VOR-DEBT-13408 | Warrants outstanding: 334358000 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| VOR-OWNER-TCG-CROSSOVER-MANAGEMENT-LLC | TCG Crossover Management, LLC | 90% | 13F overlay lists TCG Crossover Management, LLC as top holder; 80 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 |